AFINITOR (everolimus) - Neuroendocrine tumours of pancreatic origin
Opinions on drugs -
Posted on
Jun 27 2024
Reason for request
Reassessment at Transparency Committee’s request
Summary of opinion
Favourable opinion for maintenance of reimbursement in “the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease”.
Clinical Benefit
Substantial |
The Committee deems that the clinical benefit of AFINITOR (everolimus) 5 and 10 mg remains substantial in the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease. |
Clinical Added Value
no clinical added value |
Considering:
the Committee now deems that AFINITOR (everolimus) provides no clinical added value (CAV V) in the care pathway of adult patients with unresectable or metastatic, well- or |